Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.
Stock data | 2023 | Change |
---|---|---|
Price | $60.35 | N/A |
Market Cap | $16.02B | N/A |
Shares Outstanding | 265.47M | 0.00% |
Employees | 8.43K | N/A |
Shareholder Equity | 127.67B | 8.86% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.88 | N/A |
P/S Ratio | 17.54 | N/A |
P/B Ratio | 0.13 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0017 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $913.20M | N/A |
Earnings | $217.21M | N/A |
EPS | 68.69 | N/A |
Earnings Yield | 1.14 | N/A |
Gross Margin | 0.6017 | N/A |
Operating Margin | 0.2644 | N/A |
Net income margin | 0.2379 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $1.72B | N/A |
Total Debt | $388.34K | N/A |
Cash on Hand | $492.52M | N/A |
Debt to Equity | 0.0016 | -6.73% |
Cash to Debt | $1.27K | 70.69% |
Current Ratio | $8.46 | 21.06% |